ArticleGynecologic oncology2014
Diabetes mellitus and ovarian cancer: more complex than just increasing risk.
Article in Gynecologic oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 6 syntheses or guidelines pooled it, 55 citations in OpenAlex.
- Metabolic syndrome and risk of ovarian cancer: a systematic review and meta-analysis.Frontiers in endocrinology · 2023Pooled it
- Metformin Use and Mortality in Women with Ovarian Cancer: An Updated Meta-Analysis.International journal of clinical practice · 2022 · on this mapPooled it
- Pooled it
- Observational Studies on the Association Between Post-diagnostic Metformin Use and Survival in Ovarian Cancer: A Systematic Review and Meta-Analysis.Frontiers in oncology · 2019Pooled it
- Clinical outcome of treatment with serine-threonine kinase inhibitors in recurrent epithelial ovarian cancer: a systematic review of literature.Expert opinion on investigational drugs · 2016Pooled it
- Association of type 2 diabetes mellitus and the risk of colorectal cancer: A meta-analysis and systematic review.World journal of gastroenterology · 2015Pooled it
- Diabetes mellitus and the risk of ovarian cancer: an updated systematic review and meta-analysis of cohort and case-control studies.Diabetology & metabolic syndrome · 2025Review
- Comprehensive in silico analysis of prognostic and immune infiltrates for FGFs in human ovarian cancer.Journal of ovarian research · 2024Article
- Associations between Diabetes Mellitus and Selected Cancers.International journal of molecular sciences · 2024Review
- Revolutionizing ovarian cancer therapy by drug repositioning for accelerated and cost-effective treatments.Frontiers in oncology · 2024Review
- [Diabetes mellitus and the female reproductive system tumors].Problemy endokrinologii · 2023Article
- Bidirectional Mendelian randomization study of insulin-related traits and risk of ovarian cancer.Frontiers in endocrinology · 2023Article
- Metabolic risk factors of ovarian cancer: a review.JBRA assisted reproduction · 2022Review
- Potential Role of Diabetes Mellitus-Associated T Cell Senescence in Epithelial Ovarian Cancer Omental Metastasis.Life (Basel, Switzerland) · 2021Review
- Impact of metformin on survival outcome in ovarian cancer: a nationwide population-based cohort study.Journal of gynecologic oncology · 2021Article
- Germline mutations in apoptosis pathway genes in ovarian cancer; the functional role of a TP53I3 (PIG3) variant in ROS production and DNA repair.Cell death discovery · 2021Article
- Metformin and ovarian cancer: the evidence.Annals of translational medicine · 2020Review
- Associations between metabolic syndrome and gynecologic cancer.Obstetrics & gynecology science · 2020Review
- Impact of diabetes mellitus on epithelial ovarian cancer survival.BMC cancer · 2018Article
- Anticancer Activity of Metformin, an Antidiabetic Drug, Against Ovarian Cancer Cells Involves Inhibition of Cysteine-Rich 61 (Cyr61)/Akt/Mammalian Target of Rapamycin (mTOR) Signaling Pathway.Medical science monitor : international medical journal of experimental and clinical research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
objectiveDiabetes mellitus (DM) is a risk factor for endometrial cancer and is associated with poorer outcomes in breast and colon cancers. This association is less clear in epithelial ovarian cancer (EOC). We sought to examine the effect of DM on progression-free (PFS) and overall survival (OS) in women with EOC.
methodsA retrospective cohort study of EOC patients diagnosed between 2004 and 2009 at a single institution was performed. Demographic, pathologic and DM diagnosis data were abstracted. Pearson chi-square test and t test were used to compare variables. The Kaplan-Meier method and the log rank test were used to compare PFS and OS between non-diabetic (ND) and DM patients.
results62 (17%) of 367 patients had a diagnosis of DM. No differences in age, histology, debulking status, or administration of intraperitoneal chemotherapy between ND and DM patients were present, although there were more stage I and IV patients in the ND group (p=0.04). BMI was significantly different between the two groups (ND vs. DM, 27.5 vs. 30.7kg/m(2), p<0.001). While there were no differences in survival based on BMI, diabetic patients had a poorer PFS (10.3 vs. 16.3months, p=0.024) and OS (26.1 vs. 42.2months, p=0.005) compared to ND patients. Metformin use among diabetic patients did not appear to affect PFS or OS.
conclusionsEOC patients with DM have poorer survival than patients without diabetes; this association is independent of obesity. Metformin use did not affect outcomes. The pathophysiology of this observation requires more inquiry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.